Frontiers in Medicine · Nov 12, 2026
Association between gout and risk of cardiovascular outcomes: a systematic review and meta-analysis of cohort studies
By Tianyu Xu, Xinyue Zhang, Fengyuan Sun et al.
Aim: To evaluate the associations between gout and overall and specific cardiovascular outcomes using longitudinal cohort evidence. Methods: PubMed, Embase, Web of Science, and the Cochrane Library were searched from inception to July 1, 2026. Eligible prospective and retrospective cohort reports compared adults with and without gout. Selected adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were pooled using DerSimonian–Laird random-effects models. Restricted maximum likelihood estimation with Knapp– Hartung adjustment, prediction intervals, and sensitivity analyses were used to examine uncertainty. Study quality and evidence certainty were assessed using the Newcastle–Ottawa Scale and GRADE, respectively. The review was registered in PROSPERO (CRD420261404857). Results: Thirty reports were included; 29 contributed to primary analyses and one only to substitution analyses. Primary pooled HRs (95% CIs) were 1.32 (1.22–1.44) for overall cardiovascular disease, 1.36 (1.27–1.46) for coronary heart/artery or ischemic heart disease, 1.39 (1.18–1.63) for myocardial infarction, 1.72 (1.51–1.94) for heart failure, 1.20 (1.09–1.32) for stroke, and 1.23 (1.15–1.31) for cardiovascular mortality. Heterogeneity was substantial (I² = 86.64%–95.17%). The REML–Knapp–Hartung CI for stroke included 1 (HR 1.212, 95% CI: 0.991–1.482). Only the coronary prediction interval excluded 1. Egger's tests suggested small-study effects for stroke and cardiovascular mortality; tests with fewer than 10 reports were exploratory. Evidence certainty was very low for all outcomes. Conclusion: Gout was associated with increased risks of multiple cardiovascular outcomes in the primary analyses. Substantial heterogeneity, model-sensitive inference for stroke, and very low certainty warrant cautious interpretation. These associations do not establish causality or cardiovascular benefit from gout treatment.